[
  {
    "ts": "2025-12-15T09:07:12+00:00",
    "headline": "How Investors May Respond To Bristol Myers (BMY) Dividend Hike And Oncology Pipeline Momentum",
    "summary": "In recent days, Bristol Myers Squibb’s board approved a 1.6% increase in its quarterly common dividend to US$0.63 per share for February 2026 and reaffirmed its preferred dividend, while the company also secured FDA Priority Review for an Opdivo label expansion in advanced classical Hodgkin lymphoma and new approval for Breyanzi in relapsed or refractory marginal zone lymphoma. Together with extensive hematology data at the ASH meeting and progress in AI-enabled drug discovery...",
    "url": "https://finance.yahoo.com/news/investors-may-respond-bristol-myers-090712281.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "dceca5db-27ab-3e65-b477-34ed07357edd",
      "content": {
        "id": "dceca5db-27ab-3e65-b477-34ed07357edd",
        "contentType": "STORY",
        "title": "How Investors May Respond To Bristol Myers (BMY) Dividend Hike And Oncology Pipeline Momentum",
        "description": "",
        "summary": "In recent days, Bristol Myers Squibb’s board approved a 1.6% increase in its quarterly common dividend to US$0.63 per share for February 2026 and reaffirmed its preferred dividend, while the company also secured FDA Priority Review for an Opdivo label expansion in advanced classical Hodgkin lymphoma and new approval for Breyanzi in relapsed or refractory marginal zone lymphoma. Together with extensive hematology data at the ASH meeting and progress in AI-enabled drug discovery...",
        "pubDate": "2025-12-15T09:07:12Z",
        "displayTime": "2025-12-15T09:07:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-bristol-myers-090712281.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/investors-may-respond-bristol-myers-090712281.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]